To determine the impact of tocilizumab on physical function and quality of life in patients diagnosed with rheumatoid arthritis. Methods: A systematic literature review was performed to select for trials that could be used to examine the impact of tocilizumab on patients in terms of health-related physical function, quality of life, and quality of sleep. By examining background therapy, disease duration, and remission rates, we were able to determine the impact that a dose of tocilizumab has on various patients. Results: A total of 2617 tocilizumab-treated patients and 1271 controls were available for this study. Tocilizumab improved the Health Assessment Questionnaire Disability Index score statistically in comparison to the controls, with odds ratios from 1.4 to 7.0. Tocilizumab improved the physical function measure substantially more than the minimal clinically important difference (MCID) (5 units) -8.9 and 9.7 -compared to 4.1 and 5.0 for controls. Seven and nine units of improvement were observed when measuring fatigue in rheumatoid arthritis patients. Using the Epworth Sleepiness Scale, we found that sleep improved (from 7.7 [3.1] to 3.4 [2.2]). Conclusion: Tocilizumab improves function and quality of life and decreases fatigue in patients with rheumatoid arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint pain, fatigue, and even loss of certain crucial physical functions. Disease-modifying antirheumatic drugs are standard care for RA. Recent studies have shown that interleukin 6 (IL-6) plays an important role in inflammation. IL-6 is a membrane receptor produced by cells such as lymphocytes and monocytes, as well as other cell types. IL-6 activates T cells and catalyses B cell proliferation. IL-6 also stimulates osteoclast differentiation, leading to joint destruction.
Tocilizumab (TCZ) is a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody. TCZ can bind to either soluble or membrane-bound IL-6 receptors. When bound, TCZ blocks the IL-6 receptor and prevents or decreases inflammation. It has been approved by the FDA for use in patients diagnosed with moderate to severe rheumatoid arthritis. 1 The purpose of this article is to review the effect that TCZ has on patients' physical function, quality of life (QoL), level of fatigue, and sleep patterns.
Materials and methods
As seen in Figure 1 , a systematic review of TCZ was undertaken with the following keywords used as criteria for the search: TCZ, clinical trial, rheumatoid arthritis, human, and English. Also of interest were the following: health-related quality of life, activities of daily living, quality of life, fatigue, sleep, Health Assessment Questionnaire Disability Index (HAQ-DI), Short Form 36 (SF-36), European Quality of Life-5 Dimensions (EQ-5D), Functional Assessment of Chronic Illness Therapy (FACIT), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Exclusions included reviews, editorials, non-RA studies, case series, and randomized non-trials that did Tocilizumab initial title search n = 422 RA n = 309
Controlled trials n = 48
RCTs, QoL, function n = 9
Non-RA in title n = 113
Exclusions n = 36
Observational case series reviews n = 261
Figure 1 A systematic literature review was undertaken. Abbreviations: RA, rheumatoid arthritis; RCTs, randomized controlled trials; QoL, quality of life. Table 1 describes the validated measures of function, quality of life, fatigue, and sleep used in this study. [3] [4] [5] [6] [7] [8] [9] [10] Results and discussion Table 2 reviews the eight RCTs included in the systematic review.
1,2,11-16 They include 2617 TCZ-treated patients and 1271 controls. Most of the patients were followed in 24-week studies, while one study was 16 weeks, one was 52 weeks, and one was 12 weeks. The patients were quite heterogeneous, with disease duration lasting from less than one year to more than eleven years. Patients had used a wide variety of background therapy and/or previous medications. The background therapies ranged from an 8 mg per week dosage of methotrexate to having had an incomplete response to two tumor necrosis factor inhibitors. Nonetheless, all of the patients' RA activity was very vigorous, with disease activity scores, using 28 joint counts, between 6.1 and 6.8. This degree of heterogeneity precludes a credible meta-analysis. Table 3 displays the results of the health questionnaires' disability index (HAQ-DI) responses in the eight RCTs, where such data were available. 1,2,11,13-17 TCZ improved the HAQ-DI score statistically in comparison to the controls, with odds ratios from 1.4 to 7.0, favoring TCZ. The percent of patients who improved more than the MCIDs ($0.22) were noted in four studies, and the TCZ groups improved by at least that amount in 60%-68% of the patients, compared to 32%-48% of the controls. It is clear that TCZ improves disease-related function significantly and more frequently than the controls, in turn making the amount of improvement clinically important. Open-label studies using TCZ supported the RCT findings. HAQ-DI normalization (,0.5) occurred in 23%-48% of TCZ-treated patients in four trials. [18] [19] [20] [21] [22] Fatigue is very common among RA patients. The prevalence rates for fatigue in RA range from 42% to 80%. By using the Checklist of Individual Strength (CIS), persistent severe fatigue is found in 40% of RA patients (according to the FDA). Table 4 also shows the results regarding fatigue in the two double-blind RCTs in which it was measured. 1, 2 As for QoL, the patients' feelings of fatigue improved substantially more than the MCID, when compared to the control patients. The open-label studies support the conclusions stemming from the randomized trials, with 7 and 9 units of improvement. 22, 23 Overall, this important aspect of fatigue associated with RA seems to change favorably when TCZ is used.
Rheumatoid arthritis also affects patients' quality of sleep. This may be due to pain, mood changes, and/or disease activity. There was only one published study, an open-label study, that reported the effects of TCZ on sleep. 22 This study used the PSQI and ESS instruments. It showed that patients submit your manuscript | www.dovepress.com 
Dovepress

Conclusion
Based on a systematic review supplemented by the RCTs and open-label studies, TCZ improves function and quality of life, and decreases fatigue, in patients with RA; all are probably as important to patients as are joint swelling counts and so forth. It must be noted that sleep, too, may be favorably affected. This supports the general efficacy of TCZ in RA, as demonstrated through conventional measures such as joint tenderness and swelling, and through combined indices such as the ACR response criteria or the 28 joint counts.
1,2,12-16
